Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDX-1411
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MDX-1411 is a fully human, glycoengineered IgG1 monoclonal antibody that targets the extracellular domain of the human CD70 molecule, a member of the tumor necrosis factor (TNF) family. It was developed for its potential antineoplastic activity by binding to CD70-expressing cells and inducing antibody-dependent cellular cytotoxicity (ADCC), leading to immune-mediated destruction of targeted cancer cells. Preclinical studies demonstrated anti-tumor activity in models of clear cell renal cell carcinoma (ccRCC). MDX-1411 was initially developed by Medarex and later acquired by Bristol-Myers Squibb. Its primary indications included renal cell carcinoma, mantle-cell lymphoma, and chronic lymphocytic leukemia; however, clinical development has been discontinued[1][2][3][4][5].
- Other names
- anti-cd70 monoclonal antibody mdx-1411anti-cd-70 monoclonal antibody mdx-1411anti-cd 70 monoclonal antibody mdx-1411
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on MDX-1411.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDX-1411.